Small Bowel Neuroendocrine Tumors-10-Year Experience of the Ottawa Hospital (TOH).
PRRT
chemotherapy
neuroendocrine tumor
somatostatin analogues
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
09 08 2023
09 08 2023
Historique:
received:
16
06
2023
revised:
04
08
2023
accepted:
07
08
2023
medline:
28
8
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
epublish
Résumé
(1) Aim: The prevalence and incidence of small bowel NETs have increased significantly over the past two decades. This study aims to report the 10-year experience of SB-NET management at a regional cancer center in Canada. (2) Materials and methods: We conducted a retrospective study of the clinical and pathological data of patients diagnosed with biopsy-proven SB-NET at The Ottawa Hospital (TOH), Ottawa, Canada between 2011 and 2021. We report the clinicopathological characteristics of these patients, as well as their outcomes data, including survival rates. (3) Results: Between 2011 and 2021, a total of 177 SB-NET cases were identified with 51% (
Identifiants
pubmed: 37623025
pii: curroncol30080544
doi: 10.3390/curroncol30080544
pmc: PMC10453717
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7508-7519Références
Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):755-73
pubmed: 23582917
Ann Surg Oncol. 2022 Nov;29(12):7822-7832
pubmed: 35842528
J Clin Med. 2022 Jun 30;11(13):
pubmed: 35807078
PLoS One. 2013 May 15;8(5):e63364
pubmed: 23691035
Radiology. 2005 Nov;237(2):718-26
pubmed: 16192318
Ann Endocrinol (Paris). 2019 Jun;80(3):153-158
pubmed: 31072588
J Clin Oncol. 2013 Jan 20;31(3):365-72
pubmed: 23248251
Curr Probl Surg. 2020 Dec;57(12):100823
pubmed: 33234227
Ann Oncol. 2010 Oct;21 Suppl 7:vii72-80
pubmed: 20943646
Ann Oncol. 2010 Sep;21(9):1794-1803
pubmed: 20139156
Eur J Radiol. 2009 Dec;72(3):517-28
pubmed: 18829195
J Nucl Med. 2016 Jun;57(6):872-8
pubmed: 26769864
Curr Treat Options Oncol. 2018 Nov 5;19(12):69
pubmed: 30397729
J Natl Compr Canc Netw. 2012 Jun 1;10(6):785-93
pubmed: 22679120
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
Lancet. 2016 Mar 5;387(10022):968-977
pubmed: 26703889
Br J Surg. 2017 Jan;104(1):34-41
pubmed: 27706803
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Dig Dis Sci. 2011 Oct;56(10):2914-9
pubmed: 21735085
Ann Oncol. 2020 Jul;31(7):844-860
pubmed: 32272208
Lancet Oncol. 2021 Dec;22(12):1752-1763
pubmed: 34793718
Rev Endocr Metab Disord. 2017 Dec;18(4):393-410
pubmed: 29256148
J Surg Oncol. 2020 Jun;121(7):1067-1073
pubmed: 32153032
Ann Surg. 2009 Jan;249(1):63-71
pubmed: 19106677
Am J Clin Oncol. 2008 Jun;31(3):271-9
pubmed: 18525307
Lancet Oncol. 2014 Jan;15(1):e8-21
pubmed: 24384494
Am J Gastroenterol. 2007 Jul;102(7):1464-73
pubmed: 17391319
Arch Surg. 2011 Aug;146(8):953-8
pubmed: 21844436
Lancet. 2011 Dec 10;378(9808):2005-2012
pubmed: 22119496
Neuroendocrinology. 2016;103(5):552-9
pubmed: 26445315
Rev Endocr Metab Disord. 2021 Sep;22(3):615-636
pubmed: 33851319
N Engl J Med. 2014 Jul 17;371(3):224-33
pubmed: 25014687
Br J Surg. 2022 Feb 1;109(2):191-199
pubmed: 34941998
Cancer. 2015 Feb 15;121(4):589-97
pubmed: 25312765
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
J Hepatol. 2007 Oct;47(4):460-6
pubmed: 17697723
United European Gastroenterol J. 2017 Feb;5(1):5-12
pubmed: 28405316
J Clin Oncol. 2009 Oct 1;27(28):4656-63
pubmed: 19704057
Oncology. 2022;100(3):131-139
pubmed: 35078191